The Effectiveness of Different Doses of Hyaluronic Acid Injections in Knee Osteoarthritis.
- Conditions
- Knee Osteoarthritis
- Interventions
- Other: Intra-articular 20 mg, 1.0% Hyaluronic Acid InjectionOther: Intra-articular 32 mg, 1.6% Hyaluronic Acid InjectionOther: Intra-articular 48 mg, 2.0% Hyaluronic Acid Injection
- Registration Number
- NCT04786613
- Lead Sponsor
- Istanbul University
- Brief Summary
The aim of this prospective, randomized, controlled multi-centre study is to compare the effectiveness and safety of three and five injections of standard linear hyaluronic acid (HA) versus single HA injection in terms of pain intensity and functional status in patients with knee osteoarthritis.
- Detailed Description
Osteoarthritis (OA) is the most common form of chronic joint disease. A treatment option for patients diagnosed with knee osteoarthritis is intra-articular hyaluronic acid therapy. In this prospective, randomized controlled, single blind, interventional study, a total of 90 patients with stage 2-3 knee osteoarthritis according to the kellgren lawrence classification who meet the eligibility criteria will be enrolled in the study. Eligible participants will be randomly assigned to one of the three groups using computer-generated random numbers. In the first group, 2 ml linearly linked 20 mg 1.0% hyaluronic acid injection in 5 sessions, in the second group 2 ml linearly linked 32 mg 1.6% hyaluronic acid injection in 3 sessions and in the third group 2.4 ml linearly linked 48 mg 2.0% hyaluronic acid injection in a single sessions will be applied. Participants are going to evaluate before injection, at the 1-month follow-up, at the 3-month follow-up and 6-month follow-up using the visual analog scale (VAS) scores for pain during activity, at rest, and at night, with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) change in pain, stiffness and physical function score, the change in the Timed Up and Go Test (TUG) time and the change in the patient's daily activities with the numerical global patient assessment scale.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
- Unilateral or bilateral symptomatic knee pain for at least three months
- Presence of Kellgren-Lawrence stage 2-3 osteoarthritis on current anterior-posterior knee radiographs
- Functional ambulation scale stage 4-5
- Being able to attend injection and control examinations
- Intra-articular knee injection within the last six months
- History of severe trauma to the knee within the past six months
- Concomitant severe meniscus or ligament injury, surgery applied to the knee area
- Presence of severe effusion, inflammatory joint disease, infection, hematological and oncological disease in the knee.
- Having a bleeding disorder and / or using warfarin
- Kellgren-Lawrence stage 1 or stage 4 osteoarthritis on current anterior-posterior knee radiographs
- Presence of cardiac or systemic disease that may affect exercise
- The presence of neurological disease and psychiatric disease such as Parkinson's disease, stroke history that may affect balance
- Body Mass Index ≥35 kg / m²
- Allergy to hyaluranic acid products
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 20 mg, 1.0% hyaluronic acid injection groups Intra-articular 20 mg, 1.0% Hyaluronic Acid Injection In the first group, 2 ml linearly linked 20 mg 1.0% hyaluronic acid injection in 5 sessions will be applied. 32 mg, 1.6% hyaluronic acid injection groups Intra-articular 32 mg, 1.6% Hyaluronic Acid Injection In the second group, 2 ml linearly linked 32 mg 1.6% hyaluronic acid injection in 3 sessions will be applied. 48 mg, 2.0% hyaluronic acid injection groups Intra-articular 48 mg, 2.0% Hyaluronic Acid Injection In the third group 2.4 ml linearly linked 48 mg 2.0% hyaluronic acid injection in a single sessions will be applied.
- Primary Outcome Measures
Name Time Method Change from baseline activity pain score at 1-months, 3-months and 6-months Baseline, 1-month, 3-month, 6-month Visual Analogue Scale-Activity pain (0-10 point). Higher scores mean a worse outcome
- Secondary Outcome Measures
Name Time Method Change from baseline rest pain score at 1-months, 3-months and 6-months Baseline, 1-month, 3-month, 6-month Visual Analogue Scale-Rest pain (0-10 point). Higher scores mean a worse outcome
Change from baseline night pain score at 1-months, 3-months and 6-months Baseline, 1-month, 3-month, 6-month Visual Analogue Scale-Night pain (0-10 point). Higher scores mean a worse outcome
Change from baseline pain, stiffness and physical function at 1-months, 3-months and 6-months Baseline, 1-month, 3-month, 6-month Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) measures knee pain, stiffness, and physical function. The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. The sum of the scores for the three subscales gives a total WOMAC score. High scores are associated with more pain, stiffness, and poor function, while low scores indicate well-being.
Change from baseline functional balance at 1-months, 3-months and 6-months Baseline, 1-month, 3-month, 6-month The Timed Up and Go test requires the person to stand up from a standard chair in which they are sitting, walk 3 m at a comfortable speed to the marked place on the floor, turn around, walk backwards to the starting point and return to the sitting position in the chair. The time taken for the person to complete the test is measured in seconds. The timing of the test is related to the function.
Trial Locations
- Locations (1)
Istanbul University Istanbul Faculty of Medicine, Department of Physical Medicine and Rehabilitation
🇹🇷Istanbul, Fatih, Turkey